In melanoma, TNBC, and nasopharyngeal carcinoma (NPC), PD-L1 is selectively sorted into EVs to suppress the function, proliferation, and infiltration of CD8 + T cells, thereby mitigating anti-tumor immune responses [89, 90, 108–110]. The gene discussed is CD8A; the disease is melanoma.